Usefulness of in- termediate amino-terminal pro-brain natriuretic peptide concentra- tions for diagnosis and prognosis of acute heart failure. Am J Cardiol. 2006;98:386 90. 28. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type na- triuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol. 2008;101:29 38. 29. Santaguida PL, Don-Wauchope AC, Ali U, et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Fail Rev. 2014;19:507 19. 30. Hill SA, Booth RA, Santaguida PL, et al. Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev. 2014;19:421 38. 31. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the gener- al community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345 53. 32. de Lemos JA, McGuire DK, Khera A, et al. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction us- ing natriuretic peptides: results from the Dallas Heart Study. Am Heart J. 2009;157:746 53. 33. Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertro- phy and systolic dysfunction. Eur Heart J. 2006;27:3004 10. 34. Ng LL, Loke IW, Davies JE, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol. 2005;45:1043 50. 35. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, pre- dicts incident heart failure in the community. J Am Coll Cardiol. 2012;60: 1249 56. 36. Wang TJ, Wollert KC, Larson MG, et al. 